DUBLIN--(BUSINESS WIRE)--The "CDK4/6 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report ...
Clinical Trials Arena on MSN
Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer
Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results